home

MD Anderson, Theraclone Sciences form OncoResponse

TrendPharmacodia.com2015-10-09 00:00 Read   177

OncoResponse, an immuno-oncology antibody discovery company, has been launched jointly by The University of Texas MD Anderson Cancer Center and Theraclone Sciences, of Seattle, Washington.

Glycotope and Octapharma enter exclusive worldwide license agreement on human blood coagulation factors

TrendPharmacodia.com2015-10-09 00:00 Read   195

October 8, 2015, Glycotope GmbH, a global leader in glyco-optimization of biopharmaceuticals, and Octapharma AG, one of the worldwide largest human protein product manufacturers, announced today that they have entered into an exclusive worldwide licensing agreement for Glycotope's portfolio of preclinical human blood coagulation factors based on its unique and proprietary GlycoExpress(TM) (GEX(TM)) technology platform.

Proteros signs new oncology collaboration with Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA on epigenetic target

TrendPharmacodia.com2015-10-08 00:00 Read   383

Proteros biostructures GmbH today announced that it has signed an agreement with Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA ("MSD") to discover and develop small molecule compounds against an epigenetic target for the potential treatment of various types of cancer.

Lion Biotechnologies Obtains Exclusive License From NIH to Develop and Commercialize TIL in Bladder, Lung, Breast and HPV-Associated Cancers

TrendPharmacodia.com2015-10-08 00:00 Read   520

Lion Biotechnologies (LBIO), a biotechnology company that is developing novel cancer immunotherapies based on tumor-infiltrating lymphocytes (TIL), today announced that it has obtained an exclusive, worldwide license from the National Institutes of Health (NIH) to develop and commercialize TIL therapy in four additional tumor indications. Under the agreement, the NIH has granted Lion exclusive rights to certain patents to develop TIL in the treatment of bladder, lung, breast and HPV-associated cancers, including cervical and head and neck.

Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain

TrendPharmacodia.com2015-10-01 00:00 Read   985

Astellas Pharma Inc. and Chromocell Corporation today announced that they have entered into a license and collaboration agreement for the development and commercialization of therapeutics to treat neuropathic and other pain conditions.

Zai announces global collaboration and license agreement with UCB

TrendPharmacodia.com2015-09-22 00:00 Read   355

Zai Lab Ltd. announced today that it has entered into a worldwide collaboration and license agreement with UCB, a global biopharmaceutical leader (Euronext: UCB), to develop and commercialize a first-in-class monoclonal antibody for the potential treatment of autoimmune and other inflammatory diseases. The product is a clinical candidate ready for Investigational New Drug (IND)-enabling studies and expected to enter clinical Phase 1 in 2016.

Building its cardio drug portfolio, Amgen bags Dezima in $1.55B deal

TrendPharmacodia.com2015-09-16 00:00 Read   369

Amgen is acquiring Dutch biotech Dezima for $300 million up front and $1.25 billion in milestones, tackling another potential blockbuster franchise that has spurred billions of dollars in often frustrating research programs.

XenoPort plunges as investors sour fast on 'positive' psoriasis data

TrendPharmacodia.com2015-09-15 00:00 Read   299

Shares of Santa Clara, CA-based XenoPort were crushed today after the biotech touted what it called positive preliminary efficacy results from a midstage study of its oral psoriasis drug. While the biotech claimed that its drug is ready for Phase III, XenoPort faces a crowded set of late-stage rivals with a drug that posted some troubling side effects. And investors swiftly turned from upbeat to skeptical this morning as they had a chance to ponder the results, sending shares down 23% by midmorning.

Collegium waits for FDA approval with its abuse-deterrent painkiller

TrendPharmacodia.com2015-09-14 00:00 Read   399

Collegium Pharmaceuticals' hard-to-abuse opioid treatment won unanimous backing from a panel of FDA advisers, clearing the path to a likely approval next month.